Heart Failure With Reduced Ejection Fraction

Cardiovascular
4
Pipeline Programs
9
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
2 programs
1
1
Omecamtiv MecarbilPhase 31 trial
25 mg Omecamtiv MecarbilPhase 21 trial
Active Trials
NCT02695420Completed81Est. May 2017
NCT03759392Completed276Est. Jan 2022
AM-Pharma
AM-PharmaNetherlands - Utrecht
1 program
1
Ertugliflozin 5 mgPhase 31 trial
Active Trials
NCT04600921TerminatedEst. Oct 2023
Bristol Myers Squibb
1 program
1
MYK-491Phase 1/21 trial
Active Trials
NCT03447990Completed52Est. Oct 2019
Novartis
NovartisBASEL, Switzerland
2 programs
Home-based remote heart failure managementN/A1 trial
Streamlined protocolN/A1 trial
Active Trials
NCT03072693Unknown876Est. Apr 2023
NCT05021419Completed60Est. Jan 2024
Abbott
AbbottABBOTT PARK, IL
1 program
CardioMEMSN/A1 trial
Active Trials
NCT06241430Recruiting60Est. Nov 2027
Rhythm Pharmaceuticals
1 program
Coronary Sinus Lead RevisionN/A1 trial
Active Trials
NCT06342492Recruiting100Est. Dec 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AM-PharmaErtugliflozin 5 mg
CytokineticsOmecamtiv Mecarbil
Cytokinetics25 mg Omecamtiv Mecarbil
Bristol Myers SquibbMYK-491
AbbottCardioMEMS
Rhythm PharmaceuticalsCoronary Sinus Lead Revision
NovartisStreamlined protocol
NovartisHome-based remote heart failure management

Clinical Trials (8)

Total enrollment: 1,505 patients across 8 trials

NCT04600921AM-PharmaErtugliflozin 5 mg

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

Start: Jun 2021Est. completion: Oct 2023
Phase 3Terminated
NCT03759392CytokineticsOmecamtiv Mecarbil

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

Start: Apr 2019Est. completion: Jan 2022276 patients
Phase 3Completed
NCT02695420Cytokinetics25 mg Omecamtiv Mecarbil

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Start: Apr 2016Est. completion: May 201781 patients
Phase 2Completed
NCT03447990Bristol Myers SquibbMYK-491

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

Start: Feb 2018Est. completion: Oct 201952 patients
Phase 1/2Completed
NCT06241430AbbottCardioMEMS

The CardioClip Study

Start: Dec 2024Est. completion: Nov 202760 patients
N/ARecruiting
NCT06342492Rhythm PharmaceuticalsCoronary Sinus Lead Revision

Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary Sinus Lead Failure

Start: Nov 2023Est. completion: Dec 2024100 patients
N/ARecruiting
NCT05021419NovartisStreamlined protocol

Efficacy of a Streamlined Heart Failure Optimization Protocol

Start: Jul 2022Est. completion: Jan 202460 patients
N/ACompleted
NCT03072693NovartisHome-based remote heart failure management

Daily Ambulatory Remote Monitoring System For Post-Dischage Management Of ADHF

Start: Nov 2020Est. completion: Apr 2023876 patients
N/AUnknown

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr

Director, Medical Affairs

Abbott
Germany - Hesse - Eschborn
Yesterday

Therapy Development Manager

Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday

Associate Regional Clinical Consultant

Johnson & Johnson
Amersfoort, Utrecht, Netherlands
Yesterday

Medical Affairs Sr Scientist- Electrophysiology

Johnson & Johnson
Irvine, California, United States of America
Yesterday
$92K - $148K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 1,505 patients
9 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)